02575.HK
Xuanzhubio-b
HKSE · Healthcare · Drug Manufacturers - Specialty & Generic · CN
HKD 10.43
−6.21%Income statement
| Metric | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | 56.1M | 32.6M | 32.0K | — |
| Cost of Revenue | 34.4M | 45.2M | 35.6M | 30.2M |
| Gross Profit | 21.8M | (12.6M) | (35.5M) | (30.2M) |
| Operating Expenses | ||||
| R&D Expense | 120.3M | 180.9M | 238.7M | 444.9M |
| SG&A Expense | 146.3M | 413.0M | 95.6M | 100.4M |
| General & Admin Expense | — | — | — | — |
| Selling & Marketing Expense | — | — | — | — |
| Other Expenses | 8.3M | 4.7M | 4.8M | 4.7M |
| Total Operating Expenses | 274.9M | 598.7M | 339.2M | 550.1M |
| Cost and Expenses | 309.3M | 643.9M | 374.7M | 580.2M |
| Operating Income (EBIT) | (253.1M) | (611.3M) | (374.7M) | (580.2M) |
| Non-Operating | ||||
| Interest Income | 7.4M | 7.2M | 15.9M | 27.6M |
| Interest Expense | 134.5K | 329.6K | 1.3M | 1.8M |
| Net Interest Income | 7.2M | 6.9M | 14.6M | 25.9M |
| Other Non-Op Income/Expense | (13.1M) | 8.0M | 42.6M | (15.5M) |
| Non-Operating Income (excl Interest) | — | (8.3M) | (43.9M) | 13.7M |
| EBT (Pre-Tax Income) | (266.3M) | (603.3M) | (332.1M) | (595.7M) |
| Income Tax Expense | 6.5K | 6.5K | 6.6K | 5.8K |
| Bottom Line | ||||
| Net Income | (266.3M) | (603.3M) | (332.1M) | (595.7M) |
| Earnings from Cont. Ops | (266.3M) | (603.3M) | (332.1M) | (595.7M) |
| Earnings from Discont. Ops | — | — | — | — |
| Bottom Line Net Income | (266.3M) | (603.3M) | (332.1M) | (595.7M) |
| Per Share | ||||
| Basic EPS | (HK$0.51) | (HK$1.16) | (HK$0.64) | (HK$1.15) |
| Diluted EPS | (HK$0.51) | (HK$1.16) | (HK$0.64) | (HK$1.15) |
| Revenue Per Share | HK$0.11 | HK$0.06 | HK$0.00 | HK$0.00 |
| Shares | ||||
| Basic Shares Outstanding | 517.9M | 517.9M | 517.9M | 517.9M |
| Diluted Shares Outstanding | 517.9M | 517.9M | 517.9M | 517.9M |
| Profitability Metrics | ||||
| EBITDA | (220.5M) | (566.4M) | (295.3M) | (563.8M) |
| D&A | 32.6M | 36.6M | 35.5M | 30.2M |
| EBIT | (253.1M) | (603.0M) | (330.8M) | (593.9M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Dec 1, 2025